The American Journal of Medicine
Volume 122, Issue 2 , Pages 126-128 , February 2009

Anticoagulation: A Pathway to Clinical Effectiveness

  • Geoffrey D. Barnes, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Geoffrey D. Barnes, MD, Cardiovascular Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853
    • ,
  • James B. Froehlich, MD, MPH

References 

  1. Albers GW, Diener HC, Frison L, et al. SPORTIF Executive Steering Committee for the SPORTIF V Investigators Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690–698
  2. Gurwitz JH, Field TS, Radford MJ, et al. The safety of warfarin therapy in the nursing home setting. Am J Med. 2007;120:539–544
  3. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155–1166
  4. Macik BG. The future of anticoagulation clinics. J Thromb Thrombolysis. 2003;16:55–59
  5. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167:1414–1419
  6. Oake N, Fergusson DA, Forster AJ, van Walraven C. Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ. 2007;176:1589–1594
  7. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):204S–233S
  8. Ansell J, Hirsh J, Hylek E, et al. American College of Chest Physicians (Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)). Chest. 2008;133(6 Suppl):160S–198S
  9. Bosch M, van der Weijden T, Wensing M, Grol R. Tailoring quality improvement interventions to identified barriers: a multiple case analysis. J Eval Clin Pract. 2007;13:161–168
  10. Ruivard M, Berger C, Achaibi A, et al. Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France. J Gen Intern Med. 2003;18:903–907
  11. Wilson SE, Costantini L, Crowther MA. Paper-based dosing algorithms for maintenance of warfarin anticoagulation. J Thromb Thrombolysis. 2007;23:195–198
  12. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109:481–488

 Kim A. Eagle, MD, Section Editor

 Conflict of Interest: Consulting: Pfizer, Sanofi-Aventis (JBF). Speaker's Bureau: Pfizer; Sanofi-Aventis; Merck/Shering-Plough (JBF). Research Grant: Blue-Cross/Blue Shield of Michigan; Novartis (JBF). None (GDB).

 Authorship: All authors had access to the data and a role in writing the article.

PII: S0002-9343(08)00982-0

doi: 10.1016/j.amjmed.2008.10.002

The American Journal of Medicine
Volume 122, Issue 2 , Pages 126-128 , February 2009

Article Tools